The estimated Net Worth of Thomas E Shoup is at least $1.29 Milion dollars as of 24 November 2004. Thomas Shoup owns over 40,000 units of Icad Inc stock worth over $287,826 and over the last 20 years Thomas sold ICAD stock worth over $1,000,959.
Thomas has made over 2 trades of the Icad Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Thomas sold 207,069 units of ICAD stock worth $836,559 on 7 March 2005.
The largest trade Thomas's ever made was selling 207,069 units of Icad Inc stock on 7 March 2005 worth over $836,559. On average, Thomas trades about 123,535 units every 52 days since 2004. As of 24 November 2004 Thomas still owns at least 207,069 units of Icad Inc stock.
You can see the complete history of Thomas Shoup stock trades at the bottom of the page.
Thomas's mailing address filed with the SEC is C/O ICAD, INC., 4 TOWNSEND WEST, SUITE 17, NASHUA, NH, 03063.
Over the last 22 years, insiders at Icad Inc have traded over $10,970,060 worth of Icad Inc stock and bought 704,596 units worth $1,672,448 . The most active insiders traders include Anthony F Ecock, Nathaniel Dalton a Kevin C Burns. On average, Icad Inc executives and independent directors trade stock every 45 days with the average trade being worth of $39,056. The most recent stock trade was executed by Dana R Brown on 31 March 2023, trading 40,000 units of ICAD stock currently worth $52,000.
icad is a leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. icad offers a comprehensive range of high-performance, upgradeable cad solutions for mammography and advanced image analysis and workflow solutions for magnetic resonance imaging, for breast and prostate cancers and computed tomography for colorectal cancer. icad’s xoft system, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. the xoft system is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. for more information, call 877-icadnow, or visit www.icadmed.com.
Icad Inc executives and other stock owners filed with the SEC include: